Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docet...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Saad, Fred [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise - Feng, Jing ELSEVIER, 2018, official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:67 ; year:2015 ; number:2 ; pages:223-230 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.eururo.2014.08.025 |
|---|
| Katalog-ID: |
ELV018502377 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV018502377 | ||
| 003 | DE-627 | ||
| 005 | 20230623143602.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.eururo.2014.08.025 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015010000004.pica |
| 035 | |a (DE-627)ELV018502377 | ||
| 035 | |a (ELSEVIER)S0302-2838(14)00778-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 500 |q VZ |
| 084 | |a 33.25 |2 bkl | ||
| 084 | |a 31.00 |2 bkl | ||
| 100 | 1 | |a Saad, Fred |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial |
| 264 | 1 | |c 2015 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. | ||
| 650 | 7 | |a Metastatic castration-resistant prostate cancer |2 Elsevier | |
| 650 | 7 | |a Prostate-specific antigen |2 Elsevier | |
| 650 | 7 | |a Androgen receptor inhibitor |2 Elsevier | |
| 650 | 7 | |a AFFIRM trial |2 Elsevier | |
| 650 | 7 | |a Enzalutamide |2 Elsevier | |
| 700 | 1 | |a de Bono, Johann |4 oth | |
| 700 | 1 | |a Shore, Neal |4 oth | |
| 700 | 1 | |a Fizazi, Karim |4 oth | |
| 700 | 1 | |a Loriot, Yohann |4 oth | |
| 700 | 1 | |a Hirmand, Mohammad |4 oth | |
| 700 | 1 | |a Franks, Billy |4 oth | |
| 700 | 1 | |a Haas, Gabriel P. |4 oth | |
| 700 | 1 | |a Scher, Howard I. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Feng, Jing ELSEVIER |t Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |d 2018 |d official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology |g Amsterdam [u.a.] |w (DE-627)ELV000464341 |
| 773 | 1 | 8 | |g volume:67 |g year:2015 |g number:2 |g pages:223-230 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.eururo.2014.08.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 33.25 |j Thermodynamik |j statistische Physik |q VZ |
| 936 | b | k | |a 31.00 |j Mathematik: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 67 |j 2015 |e 2 |h 223-230 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
f s fs |
|---|---|
| matchkey_str |
saadfreddebonojohannshorenealfizazikarim:2015----:fiayucmsyaeiersaepcfcnieqat |
| hierarchy_sort_str |
2015 |
| bklnumber |
33.25 31.00 |
| publishDate |
2015 |
| allfields |
10.1016/j.eururo.2014.08.025 doi GBVA2015010000004.pica (DE-627)ELV018502377 (ELSEVIER)S0302-2838(14)00778-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide Elsevier de Bono, Johann oth Shore, Neal oth Fizazi, Karim oth Loriot, Yohann oth Hirmand, Mohammad oth Franks, Billy oth Haas, Gabriel P. oth Scher, Howard I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:67 year:2015 number:2 pages:223-230 extent:8 https://doi.org/10.1016/j.eururo.2014.08.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 67 2015 2 223-230 8 045F 610 |
| spelling |
10.1016/j.eururo.2014.08.025 doi GBVA2015010000004.pica (DE-627)ELV018502377 (ELSEVIER)S0302-2838(14)00778-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide Elsevier de Bono, Johann oth Shore, Neal oth Fizazi, Karim oth Loriot, Yohann oth Hirmand, Mohammad oth Franks, Billy oth Haas, Gabriel P. oth Scher, Howard I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:67 year:2015 number:2 pages:223-230 extent:8 https://doi.org/10.1016/j.eururo.2014.08.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 67 2015 2 223-230 8 045F 610 |
| allfields_unstemmed |
10.1016/j.eururo.2014.08.025 doi GBVA2015010000004.pica (DE-627)ELV018502377 (ELSEVIER)S0302-2838(14)00778-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide Elsevier de Bono, Johann oth Shore, Neal oth Fizazi, Karim oth Loriot, Yohann oth Hirmand, Mohammad oth Franks, Billy oth Haas, Gabriel P. oth Scher, Howard I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:67 year:2015 number:2 pages:223-230 extent:8 https://doi.org/10.1016/j.eururo.2014.08.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 67 2015 2 223-230 8 045F 610 |
| allfieldsGer |
10.1016/j.eururo.2014.08.025 doi GBVA2015010000004.pica (DE-627)ELV018502377 (ELSEVIER)S0302-2838(14)00778-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide Elsevier de Bono, Johann oth Shore, Neal oth Fizazi, Karim oth Loriot, Yohann oth Hirmand, Mohammad oth Franks, Billy oth Haas, Gabriel P. oth Scher, Howard I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:67 year:2015 number:2 pages:223-230 extent:8 https://doi.org/10.1016/j.eururo.2014.08.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 67 2015 2 223-230 8 045F 610 |
| allfieldsSound |
10.1016/j.eururo.2014.08.025 doi GBVA2015010000004.pica (DE-627)ELV018502377 (ELSEVIER)S0302-2838(14)00778-7 DE-627 ger DE-627 rakwb eng 610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Saad, Fred verfasserin aut Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide Elsevier de Bono, Johann oth Shore, Neal oth Fizazi, Karim oth Loriot, Yohann oth Hirmand, Mohammad oth Franks, Billy oth Haas, Gabriel P. oth Scher, Howard I. oth Enthalten in Elsevier Science Feng, Jing ELSEVIER Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise 2018 official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology Amsterdam [u.a.] (DE-627)ELV000464341 volume:67 year:2015 number:2 pages:223-230 extent:8 https://doi.org/10.1016/j.eururo.2014.08.025 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 33.25 Thermodynamik statistische Physik VZ 31.00 Mathematik: Allgemeines VZ AR 67 2015 2 223-230 8 045F 610 |
| language |
English |
| source |
Enthalten in Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise Amsterdam [u.a.] volume:67 year:2015 number:2 pages:223-230 extent:8 |
| sourceStr |
Enthalten in Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise Amsterdam [u.a.] volume:67 year:2015 number:2 pages:223-230 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Thermodynamik statistische Physik Mathematik: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Metastatic castration-resistant prostate cancer Prostate-specific antigen Androgen receptor inhibitor AFFIRM trial Enzalutamide |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| authorswithroles_txt_mv |
Saad, Fred @@aut@@ de Bono, Johann @@oth@@ Shore, Neal @@oth@@ Fizazi, Karim @@oth@@ Loriot, Yohann @@oth@@ Hirmand, Mohammad @@oth@@ Franks, Billy @@oth@@ Haas, Gabriel P. @@oth@@ Scher, Howard I. @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000464341 |
| dewey-sort |
3610 |
| id |
ELV018502377 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV018502377</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623143602.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eururo.2014.08.025</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015010000004.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV018502377</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0302-2838(14)00778-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.25</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Saad, Fred</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metastatic castration-resistant prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate-specific antigen</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Androgen receptor inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AFFIRM trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Enzalutamide</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Bono, Johann</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shore, Neal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fizazi, Karim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loriot, Yohann</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hirmand, Mohammad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franks, Billy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haas, Gabriel P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scher, Howard I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Feng, Jing ELSEVIER</subfield><subfield code="t">Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise</subfield><subfield code="d">2018</subfield><subfield code="d">official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000464341</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:67</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:223-230</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.eururo.2014.08.025</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.25</subfield><subfield code="j">Thermodynamik</subfield><subfield code="j">statistische Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.00</subfield><subfield code="j">Mathematik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">67</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">223-230</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Saad, Fred |
| spellingShingle |
Saad, Fred ddc 610 ddc 500 bkl 33.25 bkl 31.00 Elsevier Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial |
| authorStr |
Saad, Fred |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000464341 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 500 - Natural sciences & mathematics |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide Elsevier |
| topic |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 Elsevier Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide |
| topic_unstemmed |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 Elsevier Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide |
| topic_browse |
ddc 610 ddc 500 bkl 33.25 bkl 31.00 Elsevier Metastatic castration-resistant prostate cancer Elsevier Prostate-specific antigen Elsevier Androgen receptor inhibitor Elsevier AFFIRM trial Elsevier Enzalutamide |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b j d bj bjd n s ns k f kf y l yl m h mh b f bf g p h gp gph h i s hi his |
| hierarchy_parent_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| hierarchy_parent_id |
ELV000464341 |
| dewey-tens |
610 - Medicine & health 500 - Science |
| hierarchy_top_title |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000464341 |
| title |
Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial |
| ctrlnum |
(DE-627)ELV018502377 (ELSEVIER)S0302-2838(14)00778-7 |
| title_full |
Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial |
| author_sort |
Saad, Fred |
| journal |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| journalStr |
Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
223 |
| author_browse |
Saad, Fred |
| container_volume |
67 |
| physical |
8 |
| class |
610 610 DE-600 500 VZ 33.25 bkl 31.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Saad, Fred |
| doi_str_mv |
10.1016/j.eururo.2014.08.025 |
| dewey-full |
610 500 |
| title_sort |
efficacy outcomes by baseline prostate-specific antigen quartile in the affirm trial |
| title_auth |
Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial |
| abstract |
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. |
| abstractGer |
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. |
| abstract_unstemmed |
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| container_issue |
2 |
| title_short |
Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial |
| url |
https://doi.org/10.1016/j.eururo.2014.08.025 |
| remote_bool |
true |
| author2 |
de Bono, Johann Shore, Neal Fizazi, Karim Loriot, Yohann Hirmand, Mohammad Franks, Billy Haas, Gabriel P. Scher, Howard I. |
| author2Str |
de Bono, Johann Shore, Neal Fizazi, Karim Loriot, Yohann Hirmand, Mohammad Franks, Billy Haas, Gabriel P. Scher, Howard I. |
| ppnlink |
ELV000464341 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.eururo.2014.08.025 |
| up_date |
2024-07-06T18:59:20.116Z |
| _version_ |
1803857281802043392 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV018502377</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623143602.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.eururo.2014.08.025</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015010000004.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV018502377</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0302-2838(14)00778-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">33.25</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Saad, Fred</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer (PCa) after docetaxel in the randomised, phase 3, double-blind, placebo-controlled, multinational Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy (AFFIRM) trial (NCT00974311). Prostate-specific antigen (PSA) is commonly used as a marker of PCa disease burden, and the relationship of baseline PSA level to consequent treatment effect is of clinical interest.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metastatic castration-resistant prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate-specific antigen</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Androgen receptor inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">AFFIRM trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Enzalutamide</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Bono, Johann</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shore, Neal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fizazi, Karim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loriot, Yohann</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hirmand, Mohammad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franks, Billy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haas, Gabriel P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Scher, Howard I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Feng, Jing ELSEVIER</subfield><subfield code="t">Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise</subfield><subfield code="d">2018</subfield><subfield code="d">official organ of the European Association of Urology, the European Organization for Research and Treatment of Cancer - Genito-Urinary Group, the European Society for Urological Oncology and Endocrinology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000464341</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:67</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:223-230</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.eururo.2014.08.025</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">33.25</subfield><subfield code="j">Thermodynamik</subfield><subfield code="j">statistische Physik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.00</subfield><subfield code="j">Mathematik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">67</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">223-230</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401354 |